ESR1 and breast carcinoma: Tamoxifen, a selective estrogen receptor modulator (SERM) that can boasts both estrogenic and anti-estrogenic properties depending on the target tissue, is extensively used in early and metastatic stages of breast cancer treatment for HR+ patients, which inhibits estrogen-mediated cell proliferation [3].